Results 161 to 170 of about 16,042 (263)

Clinical Outcomes of Transcatheter Versus Surgical Management of Coronary Artery Disease and Aortic Stenosis

Catheterization and Cardiovascular Interventions, Volume 107, Issue 4, Page 885-887, March 1, 2026.
Nikolaos Ktenopoulos, Anastasios Apostolos, Konstantinos Karampinos, Panayotis Vlachakis, Antonios Karanasos, Maria Drakopoulou, Andreas Synetos, George Latsios, Konstantinos Tsioufis, Konstantinos Toutouzas   +9 more
wiley   +1 more source

Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics

MedComm, Volume 7, Issue 3, March 2026.
In HOMAGE, 276 plasma proteins were profiled using Olink panels. Machine learning algorithms identified galectin‐9 (GAL9), thrombospondin‐2 (THBS2), and NT‐proBNP as predictors of changes in procollagen type I C‐terminal propeptide (PICP) after spironolactone treatment.
Susana Ravassa, Nicolas Girerd, Frank Edelman, Begoña López, João Pedro Ferreira, Daniela Zurkan, Gorka San José, Iñigo Latasa, Pierpaolo Pellicori, Franco Cosmi, Johannes Petutschnigg, Stephane Heymans, Hans‐Peter Brunner‐La Rocca, Burkert Pieske, Christian Delles, Andrew L. Clark, Javier Díez, Faiez Zannad, John G. F. Cleland, Arantxa González, the HOMAGE Trial Committees and Investigators   +20 more
wiley   +1 more source

Is Off-Pump CABG Off Base?

Journal of the American College of Cardiology, 2018
Faisal G, Bakaeen, Vinod H, Thourani
openaire   +2 more sources

Phenotypes and Clinical Outcome of Heart Failure With Preserved Ejection Fraction Patients in China: Findings From the Chinese Cardiovascular Association Database‐Heart Failure Center Registry

MedComm, Volume 7, Issue 3, March 2026.
Structured graphical abstract‐text element Key Question It remains unclear whether patients with heart failure with preserved ejection fraction (HFpEF) in different phenotypes also have various clinical outcomes. Key Finding Significant differences existed in baseline characteristics and outcomes among different phenotypes; patients with HFpEF‐3 (right
Shuai Yuan, Zhonglei Xie, Xiaotong Cui, Shun Yao, Yamei Xu, Yanyan Wang, Yu Song, Kai Hu, Yugang Dong, Yuhua Liao, Weimin Li, Xinli Li, Jiefu Yang, Jingmin Zhou, Junbo Ge   +14 more
wiley   +1 more source

Anesthetic Management in Combined Off-Pump CABG and EC-IC Bypass for CAD and Moyamoya Disease. [PDF]

JACC Case Rep
Zhang J, Zhang J, Yang L, Hu D, Wang S, Li S, Tian Y, Song X, Li X, Zhou Y.   +9 more
europepmc   +1 more source

Early and Medium Outcomes of On-Pump Beating-Heart versus Off-Pump CABG in Patients with Moderate Left Ventricular Dysfunction. [PDF]

Braz J Cardiovasc Surg, 2019
Wang W, Wang Y, Piao H, Li B, Wang T, Li D, Zhu Z, Xu R, Liu K.   +8 more
europepmc   +1 more source

Neuropsychologic dysfunction after CABG: standard cardiopulmonary bypass versus off-pump CABG [PDF]

Critical Care, 2000
Oudenaarde, I, Takkenberg, JJM, van der Velden, E, Chalfont, L, Wesnes, K, van Herwerden, LA   +5 more
openaire   +1 more source

Peri‐operative rehabilitation in patients undergoing elective cardiac valve surgery: a randomised controlled trial

Anaesthesia, Volume 81, Issue 3, Page 362-372, March 2026.
Summary Introduction Patients with valvular heart disease are at high risk of postoperative pulmonary complications, which contribute to morbidity and mortality. However, few studies have focused specifically on peri‐operative rehabilitation in this patient population.
Yuting Liu, Fengyao Liu, Mingyu Xu, Haofeng Zhou, Haochen Wang, Yuanhui Liu, Xuyu He, Huanlei Huang, Tucheng Sun, Xuhua Jian, Jimei Chen, Min Wu, Yijia Sun, Peihua Cao, Jiyan Chen, Lan Guo, Huan Ma   +16 more
wiley   +1 more source

Minimizing stroke risk in off-pump CABG: the role of clampless devices and the piggyback proximal anastomosis technique. [PDF]

Front Cardiovasc Med
Baudo M, Cabrucci F, Yakobitis A, Murray C, Torregrossa G.   +4 more
europepmc   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2403-2415, March 2026.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source